- Management to provide clinical and financial updates, and outline proposed
rights issue -
- Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST -
BERGEN, Norway, May 9, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that it will hold a business update
conference call on Monday, May 15, 2023, at 10 a.m. CEST. BerGenBio's senior
management team will provide a briefing via a webcast presentation on the
Company's website, followed by a Q&A session.
Topics to be addressed during the presentation include:
Proposed Rights Issue: The Company announced on April 25, 2023, its intentions
to carry out a partially underwritten rights issue to raise gross proceeds of up
to NOK 250 million.
A Q&A document pertaining to the rights issue can from today be found in the
General Meetings (https://www.bergenbio.com/investors/general-meetings/) portion
of the Investors section of www.bergenbio.com.
BGBC008 Additional Data: Additional results of pre-planned analyses from the
Phase 2 BGBC008 trial evaluating bemcentinib in combination with pembrolizumab
in 2L+ NSCLC patients will be presented.
BGBC003 Topline Data: Topline data will be presented from the Phase 2 BGBC003
trial evaluating bemcentinib in combination with chemotherapy in patients with
AML and as a single agent in patients with MDS.
Financial Update: An update on the Company's key financial numbers will be
provided as part of the business update.
Full first quarter 2023 financial results report will currently not be
prioritized and release will be delayed to 22 June 2023.
The webcast
link (https://channel.royalcast.com/landingpage/hegnarmedia/20230515_3/) will be
available at www.bergenbio.com in the Investors/Financial Reports section.
A recording will be available shortly after the webcast has finished.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
graham.morrell@bergenbio.com
Media Relations
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.